Skip to content

Effects of a Mindfulness-Based Intervention versus Health Self-Management on Subclinical Anxiety in Older Adults with Subjective Cognitive Decline: The SCD-Well Randomized Superiority Trial.

Natalie L. Marchant, Thorsten Barnhofer, Roxane Coueron, Miranka Wirth, Antoine Lutz, Eider M. Arenaza‐Urquijo, Fabienne Collette, Géraldine Poisnel, Harriet Demnitz-King, Ann‐Katrin Schild, Nina Coll‐Padrós, Floriane Delphin-Combe, Tim Whitfield, Marco Schlosser, Julie Gonneaud, Julien Asselineau, Zuzana Walker, Pierre Krolak Salmon, José Luís Molinuevo, Eric Frison, Gaël Chételat, Frank Jessen, Olga Klimecki

Psychotherapy and Psychosomatics April 19, 2021 DOI: 10.1159/000515669 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Sample size 147
Population Older adults with subjective cognitive decline and subclinical anxiety symptoms, recruited from memory clinics at 4 European sites
Intervention Health self-management program (HSMP)
Duration 8-week intervention, with follow-up 6 months postrandomization
Measures State-Trait Anxiety Inventory (trait subscale; trait-STAI), state anxiety subscale of the State-Trait Anxiety Inventory, depression symptoms
Topics Anxiety Meditation
Keywords Humans Anxiety disorders Aged Female Cognitive dysfunction Self-management Compassion Subjective cognitive decline
Registration NCT03005652
Key findings An 8-week mindfulness-based intervention was not superior to a structurally matched health self-management program in reducing trait anxiety in older adults with subjective cognitive decline. Both groups showed similar reductions in trait anxiety after the intervention (CMBAS -3.43 points; HSMP -2.29 points), maintained at 6-month follow-up, with no between-group differences in anxiety or depression outcomes.

Abstract

Introduction: Older adults experiencing subjective cognitive decline (SCD) have a heightened risk of developing dementia and frequently experience subclinical anxiety, which is itself associated with dementia risk.

Objective: To understand whether subclinical anxiety symptoms in SCD can be reduced through behavioral interventions.

Methods: SCD-Well is a randomized controlled trial designed to determine whether an 8-week mindfulness-based intervention (caring mindfulness-based approach for seniors; CMBAS) is superior to a structurally matched health self-management program (HSMP) in reducing subclinical anxiety. Participants were recruited from memory clinics at 4 European sites. The primary outcome was change in anxiety symptoms (trait subscale of the State-Trait Anxiety Inventory; trait-STAI) from pre- to postintervention. Secondary outcomes included a change in state anxiety and depression symptoms postintervention and 6 months postrandomization (follow-up).

Results: One hundred forty-seven participants (mean [SD] age: 72.7 [6.9] years; 64.6% women; CMBAS, n = 73; HSMP, n = 74) were included in the intention-to-treat analysis. There was no difference in trait-STAI between groups postintervention (adjusted change difference: -1.25 points; 95% CI -4.76 to 2.25) or at follow-up (adjusted change difference: -0.43 points; 95% CI -2.92 to 2.07). Trait-STAI decreased postintervention in both groups (CMBAS: -3.43 points; 95% CI -5.27 to -1.59; HSMP: -2.29 points; 95% CI -4.14 to -0.44) and reductions were maintained at follow-up. No between-group differences were observed for change in state anxiety or depression symptoms.

Conclusions: A time-limited mindfulness intervention is not superior to health self-management in reducing subclinical anxiety symptoms in SCD. The sustained reduction observed across both groups suggests that subclinical anxiety symptoms in SCD are modifiable. ClinicalTrials.gov identifier: NCT03005652.

Comparable studies

Other randomized controlled trials on anxiety, most cited first.

Study Year Design Participants
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients 2000 Randomized controlled trial n = 145
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety 2016 Randomized controlled trial n = 51
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression 2016 Double-blind, placebo-controlled, crossover trial n = 29
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Hallucinogen-naïve adults reporting regular participation in religious or spiritual... 2006 Double-blind study n = 36
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Adults with advanced-stage cancer and anxiety 2010 Double-blind, placebo-controlled study n = 12

Citations in the library

Cited by 15

and 10 more in the library

Cites 8

and 3 more in the library

Explore topics